|
CONNECT WITH US
|
|
||||||||||||||
Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation.
To estimate the “age” of cancers, we reviewed data on the “time to local/regional recurrence” (LRF) following initial surgical resection for three common cancers, then applied a modified version of Collins’ law.
Exciting advances in understanding the biology of lung cancer have occurred over the last few years. These advances have led to the design of trials exploring the clinical value of newer treatment approaches.
Despite the fact that bevacizumab and cetuximab are both in an advanced stage of clinical development for use in treatment for unresectable NSCLC, several unanswered questions regarding these drugs remain.
Our knowledge regarding the efficacy and safety of chemotherapy in elderly patients is suboptimal, yet those with advanced NSCLC demonstrate the same response rates and survival benefits as their younger peers.
A 49-year-old woman insidiously developed spotty depigmentation of the chest along with thickened and bound-down skin of the upper torso. In addition, all of her fingers were swollen and her facial skin became so tight that she had difficulty smiling. What is her diagnosis?
A 71-year-old man with a smoking history of more than 100 pack-years developed non–small-cell carcinoma of the lung. During his an infusion of vancomycin he developed flushing, followed by widespread fixed erythema, muscular spasms in the back, and transient but severe hypotension. Can he ever receive vancomycin again?
A 34-year-old woman presents with pain in her left chest. Radiographic imaging shows the presence of nodules in the pleural surface. Surgical excision is performed. What is your diagnosis?
In this interview, ahead of the AACR annual meeting, we speak with Dr. Julie Brahmer, of Johns Hopkins School of Medicine, who is giving a presentation on immunotherapy in lung cancer, and is one of the clinical investigators of the extensive phase I trial of the anti–PD-1 antibody nivolumab.
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy